MarketPulse

fundraising

6 articles
Investing.comInvesting.com··Peter Frank

TPG's 40% Plunge Masks Record Year: Is the Selloff Overdone?

TPG hit record $303B AUM with 23% growth in 2025, but stock collapsed 40% in 2026 amid geopolitical and AI concerns. Analysts see buying opportunity.
APOAPOSAPOpAKKRKKRS+6private equityvaluation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Flags Going Concern Despite Clinical Trial Progress

AIM ImmunoTech disclosed going concern warnings in 2025 audited statements but expressed confidence in fundraising backed by promising Ampligen-Imfinzi trial results.
AZNAIMPhase 2 clinical trialfundraising
BenzingaBenzinga··Eva Mathew

Eclipse Raises $1.3B for Hard-Tech Push as CEO Declares 'Best Time to Build'

Eclipse closes $1.3B fundraise for hard-tech ventures in AI, robotics, manufacturing, and defense, positioning itself as operators-with-capital rather than traditional VCs.
NVDATSLARIVNAI infrastructuremanufacturing
GlobeNewswire Inc.GlobeNewswire Inc.··Uncf

UNCF New England Gala Raises Record $800K for HBCUs, Scholarships

UNCF New England Gala raises record $800,000 for historically Black colleges and universities, supporting scholarships and institutional sustainability.
DALAMJBJPMJPMpCJPMpD+7fundraisingscholarships
BenzingaBenzinga··Prnewswire

CETI Reshuffles Board, Pivots Strategy to Capitalize on Water Treatment Growth

CETI announces board reorganization and strategic refocus on water and oil filtration, with multiple product launches planned for 2026 and targeted fundraising underway.
CETIrevenue growthfundraising
BenzingaBenzinga··Bamboo Works

VivaVision Races to Complete Hong Kong IPO as Cash Runway Narrows

VivaVision Biotech rushes Hong Kong IPO as cash reserves dwindle to $5.2 million against $6.3 million quarterly burn rate. Two late-stage eye disease candidates drive investor appeal.
AMGNABTcash burnclinical trials